We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Christopher
Fox
christopher.fox@nhs.net
Dr
Christopher
Fox
christopher.fox@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
T-cell Project 2.0 is a prospective observational cohort study, enrolling patients with newly diagnosed T cell Non-Hodgkin lymphoma (rare cancers arising from mature T cells and Natural Killer (NK) cells). By studying consecutively diagnosed patients with this rare and heterogeneous group of blood cancer, this research builds on the success of the previous T cell project by responding to changes made in diagnosis, classification, staging and response evaluation witnessed over the past 5-10 years. The aim is to gain a contemporary understanding of the evolving landscape of clinical, pathobiological, radiological and therapeutic aspects of T-cell lymphoma in order to inform future clinical management from refined diagnosis through to targeted therapy.
This is a prospective, longitudinal, international, observational study of patients with histological diagnosis of Peripheral T-cell lymphoma. Eligible patients will be identified through existing clinical pathways at participating hospitals. No additional hospital visits or additional procedures will be required from patients participating in the study. Patients will be asked to provide informed consent for relevant clinical data to be recorded and analysed. Patients will also be asked to provide separate consent for additional analyses of biological samples including the existing stored diagnostic tumour tissue (no additional biopsies will be performed) as well as additional blood tests (additional blood taken at the same time as standard clinical blood tests). Patients will be treated and evaluated according to the physician’s standard practice. While patients may receive experimental interventions in the course of their care, the Registry is not designed to test any specific intervention. The study is planned to complete accrual in 2.5 years with a minimum follow-up of 2 years for each patient registered; required for the final analysis of study endpoints.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Exclusion Criteria • Diagnosis of: - EBV-positive T-cell and NK-cell lymphoproliferative diseases of childhood - Mycosis fungoides; - Sézary syndrome; - Primary cutaneous CD30-positive T-cell lymphoproliferative disorders; - Primary cutaneous peripheral T-cell lymphomas, rare subtypes; - T-cell lymphoblastic lymphoma/leukemia - T-cell prolymphocytic leukemia • Age < 18.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Christopher
Fox
christopher.fox@nhs.net
Dr
Christopher
Fox
christopher.fox@nhs.net
More information about this study, what is involved and how to take part can be found on the study website.
The study is sponsored by Angela Serra Association for Cancer Research (Italy) and funded by Angela Serra Association for Cancer Research (Italy) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 48476
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
